Idiopathic megalencephaly-possible cause and treatment opportunities: from patient to lab

Malin Almgren1, Martin Schalling, Catharina Lavebratt

  • 1Department of Molecular Medicine and Surgery, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, L8:00, SE-171 76 Stockholm, Sweden.

Insights

Idiopathic megalencephaly, characterized by an enlarged brain, may stem from neuronal development issues. Potassium channel dysfunction is implicated, and carbamazepine shows neuroprotective potential for treating brain overgrowth and epilepsy.

Area of Science:

  • Neuroscience
  • Genetics
  • Developmental Biology

Background:

  • Megalencephaly is an enlarged brain, often familial, presenting in early life.
  • Associated symptoms include seizures, motor deficits, and cognitive impairments.
  • Idiopathic megalencephalies are a diverse group with unclear causes.

Purpose of the Study:

  • To review the etiology and treatment of idiopathic megalencephalies.
  • To explore the role of neuronal development disturbances.
  • To investigate potential therapeutic agents like carbamazepine.

Main Methods:

  • Review of current literature on megalencephaly and neuronal development.
  • Analysis of a mouse model with potassium channel dysfunction.
  • Summary of data on carbamazepine's neuroprotective effects.

Main Results:

  • Neuronal proliferation, survival, or migration disturbances are hypothesized causes.
  • A genetic potassium channelopathy model demonstrated epilepsy and progressive megalencephaly.
  • Carbamazepine exhibited neuroprotective effects in brain overgrowth models.

Conclusions:

  • Potassium ion channelopathy may underlie megalencephaly with early-onset epilepsy or episodic ataxia.
  • Carbamazepine's neuroprotective properties warrant further investigation for these conditions.
  • This drug may be a potential treatment for temporal lobe epilepsy and megalencephaly.